Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up – Here’s Why
by Michael Walen · The Markets DailyZealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) shares gapped up before the market opened on Thursday . The stock had previously closed at $63.00, but opened at $67.90. Zealand Pharma A/S shares last traded at $67.90, with a volume of 185 shares changing hands.
Analysts Set New Price Targets
Several equities research analysts have recently commented on ZLDPF shares. BTIG Research upgraded Zealand Pharma A/S to a “strong-buy” rating in a report on Friday, November 28th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Zealand Pharma A/S in a research report on Tuesday, December 16th. Five analysts have rated the stock with a Strong Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy”.
View Our Latest Research Report on Zealand Pharma A/S
Zealand Pharma A/S Stock Up 6.7%
The company has a current ratio of 14.10, a quick ratio of 14.10 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $4.81 billion, a P/E ratio of 4.88 and a beta of 0.74. The stock’s fifty day moving average is $74.94 and its 200 day moving average is $69.28.
Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.90) EPS for the quarter, topping analysts’ consensus estimates of ($1.11) by $0.21. Zealand Pharma A/S had a return on equity of 55.76% and a net margin of 71.79%.The company had revenue of $7.76 million during the quarter, compared to analyst estimates of $4.54 million. Research analysts predict that Zealand Pharma A/S will post -2.19 EPS for the current fiscal year.
Zealand Pharma A/S Company Profile
Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.
Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.